Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
BESPONSA (Pfizer Pty Ltd)
Product name
BESPONSA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
195 working days (255)
Active ingredients
inotuzumab ozogamicin (rch)
Registration type
NCE/NBE
Indication
BESPONSA (powder of injection) is indicated for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.